MedTrace Logo

Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)

NCT07556120 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-04-29

No results posted yet for this study

Summary

This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.

Conditions

Interventions

DRUG

HN2301 injection

Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    collaborator OTHER

  • Shenzhen MagicRNA Biotechnology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Wen Xu · The First Affiliated Hospital of University of Science and Technology of China

  • Yan Jiang · The First Affiliated Hospital of University of Science and Technology of China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-05
Primary Completion
2027-05-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07556120 on ClinicalTrials.gov